The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

6 Oct 2021 07:00

RNS Number : 1277O
MaxCyte, Inc.
06 October 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

US57777K1060

Issuer Name

MAXCYTE, INC.

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Vitruvian Partners LLP

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

Life Tech S.à r.l.

Luxembourg

Luxembourg

5. Date on which the threshold was crossed or reached

24-Sep-2021

6. Date on which Issuer notified

28-Sep-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

3.110000

0.000000

3.110000

3122500

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

US57777K1060

3122500

3.110000

Sub Total 8.A

3122500

3.110000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

- The Vitruvian Investment Partnership III is managed by Vitruvian Partners LLP and isd eemed to be the ultimate beneficial owner of Life Tech S.à r.l.- The voting rights attached to shares disclosed herein - 3,122,500, equivalent to 3.11% of issuer's voting rights - are comprised by 2,222,500 LSE (AIM) listed shares (LSE SEDOL: BYVJZ42) and by 900,000 US NASDAQ listed shares (NASDAQ: SEDOL BKMQF66).

12. Date of Completion

28-Sep-2021

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLDKPBBKBDBFKK
Date   Source Headline
11th Jun 20187:00 amRNSMaxCyte & NIH enter CRADA for Sickle Cell Disease
21st May 20187:00 amRNSPreclinical Results at ASGCT Annual Meeting
30th Apr 20187:00 amRNSNotice of AGM and Annual Report
25th Apr 20187:00 amRNSCMO Appointment
4th Apr 20187:00 amRNSFinal Results for Year Ended 31 December 2017
15th Mar 20187:00 amRNSNotice of Full Year Results
28th Feb 20185:00 pmRNSDirector/PDMR Shareholding
15th Feb 20187:00 amRNSGrant of Options
13th Feb 20187:00 amRNSDr Richard Douglas Joins MaxCyte Board
1st Feb 20184:06 pmRNSBlock listing Interim Review
23rd Jan 20181:32 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSTrading Update
12th Jan 20185:13 pmRNSTotal Voting Rights
30th Nov 20173:26 pmRNSTotal Voting Rights
31st Oct 201712:47 pmRNSResult of AGM
16th Oct 20177:00 amRNSDeclaration of Audit Remuneration
5th Oct 20176:32 pmRNSHolding(s) in Company
5th Oct 20176:31 pmRNSHolding(s) in Company
28th Sep 20175:15 pmRNSNotice of AGM
19th Sep 20177:00 amRNSInterim Results
25th Aug 20177:00 amRNSNotice of Half Year Results
20th Jul 20176:02 pmRNSGrant of Options
12th Jul 20177:00 amRNSTrading Update
6th Jun 20177:00 amRNSResearch & Development Agreement with NIAID
31st May 20174:30 pmRNSTotal Voting Rights
2nd May 20171:42 pmRNSBlock Listing Application
25th Apr 20176:27 pmRNSHolding(s) in Company
25th Apr 20177:00 amRNSPresentation of Positive Preclinical Data
20th Apr 20176:00 pmRNSResult of Special Meeting and Issue of Equity
13th Apr 20171:00 pmRNSNotice of AGM and 2016 Annual Report and Accounts
31st Mar 201712:40 pmRNSResults of Placing
31st Mar 20177:00 amRNSProposed Placing to raise up to approx. £20.0m
20th Mar 20177:00 amRNSFull Year Results
14th Mar 20177:00 amRNSCRISPR THERAPEUTICS/CASEBIA COMMERCIAL LICENSE
2nd Mar 20177:00 amRNSMaxCyte to Present Pre-Clinical CARMA Data at AACR
1st Mar 20177:00 amRNSNotice of Full Year Results
24th Jan 20177:00 amRNSTrading Update
12th Jan 20177:00 amRNSStudy Published in Science Translational Medicine
3rd Jan 20172:49 pmRNSIssue of Equity from exercise of Share Options
21st Dec 20167:00 amRNSMaxCyte Announces Collaboration to Advance CARMA
6th Dec 20169:34 amRNSIssue of Equity from exercise of Share Options
27th Oct 20167:00 amRNSResult of Annual General Meeting
21st Oct 20167:43 amRNSDirector/PDMR Shareholding
28th Sep 20166:00 pmRNSGrant of Options
27th Sep 20167:00 amRNSFinancial Results for Six Months ended 30 June 16
19th Sep 20165:00 pmRNSNotice of AGM
6th Sep 20167:00 amRNSMaxCyte Bolsters Distributor Network in Asia
6th Sep 20167:00 amRNSNotice of Interim Results
12th Jul 20167:00 amRNSTrading Update
14th Jun 20167:00 amRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.